MedAnnex is a dynamic biotechnology company developing new treatments for patients with autoimmune diseases.

Our novel monoclonal antibody – annexuzlimab – has shown significant activity in several autoimmune conditions, including rheumatoid arthritis and multiple sclerosis.

Latest News

November 2017

MedAnnex partners with University College London (UCLC) to further explore annexuzlimab’s potential as a new therapeutic for SLE

November 2017

MedAnnex confirms a 4-year Medical Research Scotland PhD studentship (Glasgow University), exploring the role of annexin and mechanism of action of annexuzlimab in chronic inflammatory disease